Drug intelligence / Profile preview

N-iminoethyl-L-lysine

Development stage: Preclinical
Lead developer: Pfizer
Modality: Small Molecules
Administration: In Vitro, In Vivo

Overview

N-iminoethyl-L-lysine (commonly known as L-NIL) is a synthetic, small molecule that acts as a potent and selective inhibitor of inducible nitric oxide synthase (iNOS). It shows high selectivity for iNOS over constitutive nitric oxide synthase isoforms and is used primarily as a pharmacological tool in research to investigate the role of iNOS in pathophysiological processes and disease models. Developed for biochemical and animal model investigation, its main action is competitive, reversible inhibition of iNOS-dependent nitric oxide production[1][7][9].

Other names: L-NILN6-(1-iminoethyl)-L-lysineL-N6-(1-iminoethyl)lysineL-Lysine ω-acetamidineN6-(1-iminoethyl)lysine dihydrochloride

Targets

NOS2 (Nitric Oxide Synthase 2)

Beyond the preview

Go deeper on N-iminoethyl-L-lysine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-iminoethyl-L-lysine.

Explore the full profile